Table 1. Major trials of postoperative RT for gastric cancer.

Trial	Phase	Country/countries	Randomization	N	RT technique	D2 dissection rate	pN+ rate	DFS/RFS/EFS	OS
INT-0116	III	USA	Postoperative CRT (45 Gy + 5-FU/LCV) vs. Obs	556	AP/PA (2D)	10%	85%	25% vs. 14% (P<0.001), 10-year	26% vs. 17% (P=0.005), 10-year
ARTIST	III	South Korea	Postoperative XPRT (45 Gy + concurrent capecitabine) vs. XP	458	AP/PA (2D/3D)	100%	86%	74% vs. 68% (P=0.092), 5-year	75% vs. 73% (P=0.53), 5-year
ARTIST-2	III	South Korea	Postoperative SOX + RT (45 Gy) vs. SOX vs. S-1 (3-arm)	538	Not reported	100%	100%	73% vs. 78% vs. 65% (P=0.67 for SOX+RT vs. SOX), 3-year	Not reported
CRITICS	III	Netherlands, Sweden, Denmark	Postoperative CRT (45 Gy + capecitabine + cisplatin) vs. EOC/ECC	788	3D or IMRT allowed	6.8%	51.1% (ypN+)	38% vs. 39% (P=0.92), 5-year	40% vs. 42% (P=0.90), 5-year

RT, radiotherapy; N, number; pN+, pathologically node-positive; LR, local relapse; DFS, disease-free survival; RFS, relapse-free survival; EFS, event-free survival; OS, overall survival; INT, Intergroup; CRT, chemoradiation; 5-FU, 5-fluouracil; LCV, leucovorin; AP, anteroposterior; PA, posteroanterior; XPRT, capecitabine/cisplatin plus radiotherapy; XP capecitabine/cisplatin; EOC, epirubicin/oxaliplatin/capecitabine; ECC, epirubicin/cisplatin/capecitabine; IMRT, intensity-modulated radiotherapy; ypN+, pathologically-node-positive after neoadjuvant therapy.